Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;92(3):357-60.
doi: 10.1136/hrt.2004.054015. Epub 2005 Aug 5.

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

P M Elliott  1 , H Kindler, J S Shah, B Sachdev, O E Rimoldi, R Thaman, M T Tome, W J McKenna, P Lee, P G Camici
Affiliations

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

P M Elliott et al. Heart. 2006 Mar.

Abstract

Objective: To measure coronary flow reserve (CFR), an index of microvascular function, in Anderson-Fabry disease (AFD) at baseline and after enzyme replacement therapy (ERT).

Methods and results: Mean (SD) myocardial blood flow (MBF) at rest and during hyperaemia (adenosine 140 microg/kg/min) was measured in 10 male, non-smoking patients (53.8 (10.9) years, cholesterol 5.5 (1.3) mmol/l) and in 24 age matched male, non-smoking controls (52.0 (7.6) years, cholesterol 4.5 (0.6) mmol/l) by positron emission tomography (PET). Resting and hyperaemic MBF and CFR (hyperaemic/resting MBF) were reduced in patients compared with controls (0.99 (0.17) v 1.17 (0.25) ml/g/min, p < 0.05; 1.37 (0.32) v 3.44 (0.78) ml/g/min, p < 0.0001; and 1.41 (0.39) v 3.03 (0.85), p < 0.0001, respectively). This coronary microvascular dysfunction was independent of cholesterol concentrations. PET was repeated in five patients after 10.1 (2.3) months of ERT; resting and hyperaemic MBF and CFR were unchanged after ERT (0.99 (0.16) v 0.99 (0.16) ml/g/min; 1.56 (0.29) v 1.71 (0.3) ml/g/min; and 1.6 (0.37) v 1.74 (0.28), respectively; all not significant).

Conclusions: The results of the present study show that patients with AFD have very abnormal coronary microvascular function. These preliminary data suggest that ERT has no effect on coronary microvascular dysfunction. Further work is necessary to determine whether treatment at an earlier stage in the course of the disease may improve coronary microvascular function in patients with AFD.

PubMed Disclaimer

References

    1. Desnick R J, Ioannou Y A, Eng C M. a‐Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw‐Hill, 20013733–3774.
    1. Moon J C, Sachdev B, Elkington A G.et al Gadolinium enhanced cardiovascular magnetic resonance in Anderson‐Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003242151–2155. - PubMed
    1. Shah J S, Lee P, Hughes D.et al The natural history of left ventricular systolic function in Anderson‐Fabry disease. Heart 200591533–534. - PMC - PubMed
    1. Sachdev B, Takenaka T, Teraguchi H.et al Prevalence of Anderson‐Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 20021051407–1411. - PubMed
    1. Maron B J, Gottdiener J S, Epstein S E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 198148418–428. - PubMed

Publication types

MeSH terms

Substances